Lenacapavir plus islatravir is a new level of highly active antiretroviral therapy for human immunodeficiency virus infection. Gilead Sciences and Merck & Co. continue their in-depth scientific research.
Lenacapavir plus islatravir is a new level of highly active antiretroviral therapy for human immunodeficiency virus infection. Gilead Sciences and Merck & Co. continue their in-depth scientific research.